172 related articles for article (PubMed ID: 30031101)
1. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
[TBL] [Abstract][Full Text] [Related]
2. Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma.
Zhang G; Yang DL; Zheng G; Liang Y
Oncol Lett; 2020 Jun; 19(6):3871-3880. PubMed ID: 32382335
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications.
Liu Y; Zheng G; Yang D; Guo X; Tian L; Song H; Liang Y
Intern Med J; 2021 Jun; 51(6):896-904. PubMed ID: 32510678
[TBL] [Abstract][Full Text] [Related]
4. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
6. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
Yin W; Zheng G; Yang K; Song H; Liang Y
World J Surg Oncol; 2018 Mar; 16(1):44. PubMed ID: 29506546
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract][Full Text] [Related]
8. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
Yin W; Zheng G; Su S; Liang Y
Oncol Res Treat; 2019; 42(6):334-341. PubMed ID: 31063993
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Am J Clin Oncol; 2015 Aug; 38(4):388-94. PubMed ID: 26214083
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
[TBL] [Abstract][Full Text] [Related]
11. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.
Wang L; Li HG; Xia ZS; Lü J; Peng TS
Chin Med J (Engl); 2010 Dec; 123(24):3554-8. PubMed ID: 22166630
[TBL] [Abstract][Full Text] [Related]
12. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.
Türkcü G; AlabalIk U; Keles AN; Ibiloglu I; Küçüköner M; Sen HS; Büyükbayram H
Pol J Pathol; 2016 Jun; 67(2):108-13. PubMed ID: 27543864
[TBL] [Abstract][Full Text] [Related]
13. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases.
Pavlisko EN; Roggli VL
Am J Surg Pathol; 2015 Nov; 39(11):1568-75. PubMed ID: 26371785
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of malignant peritoneal mesothelioma: A population-based study.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Cancer Epidemiol; 2017 Dec; 51():81-86. PubMed ID: 29080447
[TBL] [Abstract][Full Text] [Related]
16. Well-differentiated papillary mesothelioma with invasive foci.
Churg A; Allen T; Borczuk AC; Cagle PT; Galateau-Sallé F; Hwang H; Murer B; Murty VV; Ordonez N; Tazelaar HD; Wick M
Am J Surg Pathol; 2014 Jul; 38(7):990-8. PubMed ID: 24618613
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
[TBL] [Abstract][Full Text] [Related]
18. Current trends in the management of malignant peritoneal mesothelioma.
Miura JT; Johnston FM; Gamblin TC; Turaga KK
Ann Surg Oncol; 2014 Nov; 21(12):3947-53. PubMed ID: 24841356
[TBL] [Abstract][Full Text] [Related]
19. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
20. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
